What the FDA labels say about taking them together
Dexlansoprazole and digoxin
Dexlansoprazole's FDA label of February 17, 2025 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name dexlansoprazole. The dexlansoprazole label: “Potential for increased exposure of digoxin.”
Check it at the source: the dexlansoprazole FDA label on DailyMed (effective February 17, 2025, Takeda Pharmaceuticals America, Inc.); the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.).
What does the dexlansoprazole label say about digoxin?
Dexlansoprazole label, drug interactionsClinical Impact: Potential for increased exposure of digoxin. Intervention: Monitor digoxin concentrations. Dose adjustment of digoxin may be needed to maintain therapeutic drug concentrations. See prescribing information for digoxin.
Dexlansoprazole label, warnings and precautionsFor patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ].
Source: FDA drug label (Dexilant), Takeda Pharmaceuticals America, Inc., effective February 17, 2025 (SPL set 9819f033-3bbe-442e-8e92-45fec77b237d), via openFDA; the full label on DailyMed
What does the digoxin label say about dexlansoprazole?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name dexlansoprazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexlansoprazole | Digoxin | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Heart failure, Atrial fibrillation |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $3.71 per capsule 60 mg capsule | $0.133 per tablet 125 mcg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once